Boston-Based Vertex Pharmaceuticals Just Delivered a Kidney Disease Breakthrough
While most of Wall Street was still digesting the weekend business news, Vertex Pharmaceuticals dropped a clinical data release that sent its stock jumping more than 6% in premarket trading. The reason: povetacicept, the company’s experimental drug for a serious and poorly treated kidney disease, just hit its primary endpoint in a Phase 3 trial […]
Boston-Based Vertex Pharmaceuticals Just Delivered a Kidney Disease Breakthrough Read More »










